FDA Forces Healthcare Marketers to Build Trust For AI Devices That Don't yet Exist

The FDA issued a discussion paper on August 18, 2026, requesting public feedback on how to regulate generative AI-enabled medical devices—a move that forces healthcare marketers into an unfamiliar position: preparing patient engagement strategies for technologies that don't yet have finalized regulatory pathways . Marketing leaders now face a dual challenge. They must educate patients about AI capabilities sophisticated enough to reshape diagnosis and treatment while building trust frameworks before the FDA finalizes what "safe and effective" actually means for these tools.

The discussion paper proposes a two-axis risk assessment framework and introduces "competency assessment" for premarket evaluation—a concept borrowed from physician credentialing that would require non-clinical device benchmarking and clinical confirmation before devices reach patients . The public comment period closes October 19, 2026, giving device manufacturers and healthcare systems fewer than 60 days to shape regulations that will determine which AI medical devices reach market and how quickly .

"Artificial intelligence is transforming medicine, and the United States must lead in shaping how this technology is developed and used safely and responsibly," said Acting FDA Commissioner Kyle Diamantas, emphasizing the Trump Administration's priority to accelerate innovative medical products to market through AI .

Healthcare marketers should care about this regulatory evolution even if they don't market medical devices. The FDA's competency assessment framework previews how all patient-facing AI communications will be scrutinized—not just for accuracy, but for whether the technology demonstrates measurable competence before patients encounter marketing claims. Patient acquisition strategies built on AI-powered triage, symptom checkers, or personalized treatment recommendations operate in the same trust ecosystem the FDA is now defining. When the agency finalizes standards for GenAI medical devices, expect those principles to cascade into enforcement actions on AI-powered patient engagement tools that make implicit health claims.

The Competency Model Rewrites Healthcare AI Marketing Timelines

The FDA's Digital Health Center of Excellence framed the discussion paper around a physician-inspired credentialing model . This matters for marketers because it shifts regulatory evaluation from static approval to ongoing competency demonstration—the same way physicians maintain board certifications through continued education and performance assessments.

For device manufacturers, this approach extends marketing timelines. Traditional medical device launches follow a predictable path: premarket approval, launch campaigns, sales force activation. GenAI-enabled devices face an additional layer: demonstrating competency through benchmarking exercises and clinical confirmation that the AI performs as intended across diverse patient populations .

Healthcare systems marketing AI-powered diagnostic tools or treatment planning software must now account for this competency requirement in patient communications. Marketing claims like "AI-powered precision" or "personalized treatment recommendations" require documentation that the underlying GenAI model has been benchmarked against clinical standards—not just validated in controlled studies. The FDA specifically calls out foundation models and agentic AI systems as areas requiring distinct regulatory considerations .

The timeline compression is real. The FDA opened docket FDA-2026-N-7874 with a 60-day comment period ending October 19, 2026 . Device manufacturers with GenAI products in development pipelines must submit feedback while simultaneously preparing marketing strategies for regulatory scenarios that don't yet exist. Marketing leaders should anticipate at least 12-18 months between the close of public comment and finalized guidance, meaning 2027 at the earliest for clear regulatory pathways.

Patient Education Competes With Technology Velocity

GenAI medical devices introduce risks distinct from traditional software and AI-enabled devices, according to FDA Center for Devices and Radiological Health Director Michelle Tarver . She emphasized the need for regulatory approaches that "keep pace with the rapid innovation of digital health technologies" while safeguarding patients .

This velocity creates a patient education gap that marketers must fill. Patients understand that their physician uses clinical judgment. They don't yet understand how a GenAI system exercises "competency" or what benchmarks determine whether an AI is qualified to inform their treatment decisions. Marketing teams face the challenge of building literacy around AI competency without triggering concerns about experimental technology.

The standardization challenge extends beyond medical devices. The Association of National Advertisers released measurement standardization guidelines for retail media networks on the same day the FDA issued its GenAI discussion paper . While seemingly unrelated, both initiatives address the same underlying problem: how to build trust in systems that lack common evaluation frameworks. ANA's effort to standardize retail media measurement—including 14-day loopback windows and unified outcome definitions—demonstrates that marketers across industries struggle to compare performance when platforms define success differently .

Healthcare marketers promoting GenAI-enabled devices or services will face parallel measurement challenges. If the FDA establishes competency benchmarks that vary by clinical use case, how do marketing teams explain to patients why an AI is "competent" for radiology interpretation but requires physician oversight for treatment planning? The lack of standardized competency definitions creates communication complexity that most patient education materials aren't designed to handle.

Post-Market Monitoring Creates Continuous Marketing Obligations

The FDA's discussion paper outlines "risk-proportionate postmarket monitoring" for GenAI devices . This approach acknowledges that AI model performance can drift over time as patient populations change or as the AI learns from new data. For marketers, postmarket monitoring translates to continuous patient communication obligations that extend well beyond launch campaigns.

Traditional medical device marketing follows a product lifecycle: pre-launch awareness, launch education, maintenance messaging, and eventual end-of-life communication. GenAI devices require a different model. If the FDA requires ongoing competency demonstration, marketing teams must develop patient communication strategies that explain why an AI device their physician recommended six months ago now has updated competency benchmarks or modified clinical use parameters.

DHCoE Director Rick Abramson described GenAI-enabled medical devices as "poised to reshape the health technology landscape" and positioned the FDA discussion paper as advancing "the frontiers of regulatory science" . That phrase—advancing frontiers—signals that regulatory expectations will evolve as the science develops. Marketing leaders should prepare for scenario planning exercises that account for multiple regulatory outcomes, including staged approvals, conditional clearances, and post-market study requirements that affect patient messaging.

The financial implications are substantial. Postmarket monitoring requirements drive patient follow-up costs, data collection infrastructure, and potentially re-education campaigns if competency benchmarks change. Healthcare systems that market AI-enabled services to patients need budget flexibility for sustained communication programs that explain evolving regulatory status without undermining patient confidence.

HIPAA and AI-Generated Clinical Communications Converge

While the FDA discussion paper focuses on device regulation, healthcare marketers must consider how HIPAA applies to AI-generated patient communications. GenAI systems that create personalized patient education materials, generate treatment recommendations, or draft clinical summaries potentially create protected health information that falls under HIPAA's privacy and security rules.

Marketing teams using GenAI tools to scale patient engagement—such as AI-generated email sequences, chatbot interactions, or personalized content recommendations—need documented business associate agreements with AI vendors. The FDA's emphasis on transparency in measurement methods and logic aligns with HIPAA's requirement for documented privacy practices. If the FDA requires GenAI device manufacturers to disclose how their models make clinical decisions, healthcare marketers using similar AI tools for patient communications should anticipate parallel transparency obligations.

State-level AI regulations compound compliance complexity. Marketing teams operating across multiple states must track varying requirements for AI disclosure, consent, and data usage. The FDA's national regulatory framework provides a baseline, but state attorneys general have demonstrated willingness to pursue healthcare AI cases under consumer protection statutes when patient communications create misleading impressions about AI capabilities.

The 1ness Take

Healthcare marketers face a strategic choice: wait for finalized FDA guidance before developing GenAI patient communication strategies, or build flexible frameworks now that accommodate multiple regulatory outcomes.

We recommend the latter. The FDA's competency assessment approach provides enough directional clarity to begin patient education infrastructure development. Marketing teams should create modular content libraries that explain AI competency concepts at different literacy levels, develop visual frameworks that illustrate how AI systems are benchmarked and validated, and establish governance processes for updating patient communications as regulatory guidance evolves.

The physician-inspired credentialing model offers a communication bridge. Patients understand that doctors complete medical school, residency, board certification, and continuing education. Marketing materials can draw parallels between physician competency maintenance and AI system benchmarking without oversimplifying the technical differences. This approach builds on existing patient mental models rather than requiring entirely new conceptual frameworks.

Invest in cross-functional teams now. The FDA's 60-day comment period creates an opportunity for marketing leaders to collaborate with regulatory affairs, clinical informatics, and legal teams to shape public feedback that considers patient communication implications. Device manufacturers and health systems that submit comments addressing patient education and trust-building alongside technical regulatory considerations will be better positioned when guidance finalizes.

Prepare for staged market entry. The FDA's discussion of risk-proportionate approaches suggests that high-risk GenAI applications may face more stringent premarket requirements than lower-risk tools. Marketing strategies should account for phased launches where AI capabilities become available to patients incrementally as competency benchmarks are met. This requires campaign architectures that can activate in stages rather than big-bang product launches.

Finally, build measurement frameworks that mirror the FDA's emphasis on ongoing evaluation. If GenAI devices require continuous competency demonstration, patient engagement metrics should track comprehension of AI capabilities over time, not just initial awareness. Implement longitudinal patient surveys that assess whether understanding of AI competency improves as regulatory clarity increases and clinical evidence accumulates.

The standardization challenges facing retail media networks—where marketers struggle to compare performance across platforms with inconsistent definitions—preview the measurement fragmentation healthcare marketers will encounter with GenAI devices . Establish internal standards for AI competency communication now, before the market fragments around incompatible frameworks.

The Takeaway

Healthcare marketing leaders should take three immediate actions:

The FDA's regulatory framework development timeline suggests healthcare marketers have 12-18 months to build patient communication infrastructure before guidance finalizes. Organizations that use this window to establish flexible frameworks will lead in a market where AI competency demonstration becomes table stakes for patient trust.